# MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients

> **NCT04212221** · PHASE1,PHASE2 · TERMINATED · sponsor: **Zai Lab (Shanghai) Co., Ltd.** · enrollment: 89 (actual)

## Conditions studied

- Advanced Hepatocellular Carcinoma (HCC)

## Interventions

- **DRUG:** MGD013 monotherapy
- **DRUG:** MGD013 in combination with Brivanib Alaninate

## Key facts

- **NCT ID:** NCT04212221
- **Lead sponsor:** Zai Lab (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-04-20
- **Primary completion:** 2022-04-27
- **Final completion:** 2022-04-27
- **Target enrollment:** 89 (ACTUAL)
- **Why stopped:** Due to the rapid shifting of liver cancer disease landscape and the company's adjustment of development strategy.
- **Last updated:** 2024-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04212221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04212221, "MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04212221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*